Updates on Oncogene-Driven NSCLC from Vienna: Osimertinib resistance
In this episode, experts explore new data related to EGFR TKI resistance, specifically resistance to osimertinib. Listen to our experts evaluating the real-world data on most common resistance mechani...
13 Elo 202210min
Updates on Oncogene-Driven NSCLC from Vienna: Targeting KRAS G12C mutation
In this episode, our experts discuss current and new strategies for targeting KRAS G12C mutation. Hear about emerging strategies to enhance activity of current treatment options in this molecular subt...
12 Elo 202211min
Updates on Oncogene-Driven NSCLC from Vienna: Targeting METex 14 skipping mutations
In this episode two experts discuss new data presented at WCLC on targeting MET ex14 skipping mutations. Listen to the latest evidence on managing this rare molecular subtype and how these data may im...
11 Elo 202214min
Promising Strategies to Enhance Efficacy of (Chemo)radiotherapy in LA SCCHN
Novel strategies are needed to improve outcomes for patients with LA SCCHN. Enhancing chemoradiation by targeting Inhibitor of Apoptosis Proteins (IAPs) – a class of proteins that regulate apoptosis a...
29 Kesä 202216min
The Role of Immunotherapy in LA SCCHN
Based on improved survival, PD-1 immune checkpoint inhibitors (± chemotherapy) have become the standard of care for patients with recurrent/metastatic SCCHN. However, in patients with locally advanced...
22 Kesä 202219min
Current Standard of Care for LA SCCHN
More than half of patients with head and neck cancer present with locally advanced disease, and high-risk patients continue to have a poor prognosis. The treatment of locally advanced squamous cell ca...
15 Kesä 202218min
Best Practice Exchange in advanced UC - Clinical case 2: Immunotherapy adverse event management
In our final episode of a series of advanced urothelial case discussions, two experts review the case of a patient with immunotherapy-related adverse events. Listen in to hear about the latest guideli...
16 Maalis 202217min
Best Practice Exchange in advanced UC - Clinical case 1: Cisplatin-ineligible first-line treatment with immunotherapy
In this penultimate episode of our podcast exploring treatment options for patients with advanced urothelial cancer, our experts discuss the latest data on immunotherapy options for cisplatin-ineligib...
9 Maalis 202221min
